NasdaqCM - Nasdaq Real Time Price USD

bioAffinity Technologies, Inc. (BIAFW)

Compare

0.5015

+0.0399

+(8.64%)

As of 10:18:57 AM EST. Market Open.

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

SAN ANTONIO, January 13, 2025--bioAffinity Technologies reports positive results of the 2024 beta test market launch of CyPath Lung in Texas.

Business Wire 3 hours ago

BIAF
-9.60%
BIAFW
+8.64%
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 ...

ACCESSWIRE 3 days ago

BIAF
-9.60%
BIAFW
+8.64%
ENLV
bioAffinity Technologies Boosts Sales with CyPath Lung

bioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an update. bioAffinity Technologies, Inc. reports a successful year in 2024, significantly boosting sales and operations through its lung cancer detection product, CyPath Lung. The company plans to expand its market presence in 2025, leveraging its growth in the U.S. healthcare system and focusing on key regions and markets, including the VA and military sectors, to further increase the accessibility and adoption of its test. More about bio

TipRanks 23 days ago

BIAF
-9.60%
BIAFW
+8.64%
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

SAN ANTONIO, December 17, 2024--bioAffinity Technologies President and CEO Maria Zannes will be featured on RedChip Companies' investor webinar on Thursday, Dec. 19.

Business Wire 27 days ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Set for Continued Expansion in 2025

SAN ANTONIO, December 12, 2024--bioAffinity reports successful execution of its pilot marketing program and steady growth in sales of the CyPath® Lung test in 2024.

Business Wire last month

BIAF
-9.60%
BIAFW
+8.64%
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

SAN ANTONIO, December 05, 2024--NAVREF hosts a joint presentation by bioAffinity and Federal Supply System officials about adding CyPath® Lung to the VA healthcare system.

Business Wire last month

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

SAN ANTONIO, November 14, 2024--bioAffinity Technologies releases financial results for the three months ended September 30, 2024.

Business Wire last month

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

SAN ANTONIO, November 04, 2024--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development.

Business Wire 2 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

SAN ANTONIO, October 30, 2024--bioAffinity Technologies receives a Japanese patent for the method behind the CyPath® Lung diagnostic test for early-stage lung cancer.

Business Wire 2 months ago

BIAF
-9.60%
BIAFW
+8.64%
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent pri

PR Newswire 2 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

SAN ANTONIO, October 21, 2024--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement

Business Wire 2 months ago

BIAF
-9.60%
BIAFW
+8.64%
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock in a registered direct offering at a price of $1.30 per share

PR Newswire 2 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

SAN ANTONIO, October 18, 2024--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement.

Business Wire 2 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

SAN ANTONIO, October 16, 2024--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique biological samples like sputum used in CyPath® Lung.

Business Wire 2 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

SAN ANTONIO, October 10, 2024--bioAffinity Technologies names J. Michael Edwards as Chief Financial Officer.

Business Wire 3 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

SAN ANTONIO, October 09, 2024--bioAffinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at risk for lung cancer.

Business Wire 3 months ago

BIAF
-9.60%
BIAFW
+8.64%
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

SAN ANTONIO, Texas, September 18, 2024--Study demonstrates how CyPath Lung diagnostic test for lung cancer can significantly reduce healthcare costs for both public and private insurers.

Business Wire 3 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

SAN ANTONIO, August 23, 2024--J. Michael Edwards replaces Michael Dougherty as bioAffinity CFO; Dougherty is leaving for a position in the energy sector in the Pacific Northwest.

Business Wire 4 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

SAN ANTONIO, Texas, August 14, 2024--bioAffinity Technologies reports financial results and operational highlights for the quarter ended June 30, 2024.

Business Wire 4 months ago

BIAF
-9.60%
BIAFW
+8.64%
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

SAN ANTONIO, August 05, 2024--bioAffinity Technologies announces closing of registered direct offering, private placement and warrant inducement for gross proceeds of $1.75 million

Business Wire 5 months ago

BIAF
-9.60%
BIAFW
+8.64%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

bioAffinity Technologies, Inc. (BIAFW)

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies Boosts Sales with CyPath Lung

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

bioAffinity Technologies Set for Continued Expansion in 2025

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million